Literature DB >> 6807081

Valproic acid in the treatment of intractable absence seizures in children: a single-blind clinical and quantitative EEG study.

G Erenberg, A D Rothner, C E Henry, R P Cruse.   

Abstract

A 12-week single-blind study used valproic acid in the treatment of refractory, simple and complex absence (petit mal) seizures in 17 children. The clinical seizure control was compared with the number and duration of electrical discharges on six-hour EEG recordings before and during therapy. Sixteen patients showed clinical improvement. Fourteen had greater than 75% clinical improvement and ten patients became free of absence seizures. Side effects were mild, but two patients experienced transient, asymptomatic thrombocytopenia. Good correlation between clinical response and decreasing seizure activity on the EEG occurred in the seizure-free patients.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6807081     DOI: 10.1001/archpedi.1982.03970420050011

Source DB:  PubMed          Journal:  Am J Dis Child        ISSN: 0002-922X


  9 in total

1.  Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents.

Authors:  Francesco Brigo; Stanley C Igwe; Simona Lattanzi
Journal:  Cochrane Database Syst Rev       Date:  2019-02-08

2.  Epigenetic Downregulation of Scn3a Expression by Valproate: a Possible Role in Its Anticonvulsant Activity.

Authors:  Na-Na Tan; Hui-Ling Tang; Guo-Wang Lin; Yong-Hong Chen; Ping Lu; Hai-Jun Li; Mei-Mei Gao; Qi-Hua Zhao; Yong-Hong Yi; Wei-Ping Liao; Yue-Sheng Long
Journal:  Mol Neurobiol       Date:  2016-03-25       Impact factor: 5.590

Review 3.  Treatment of typical absence seizures and related epileptic syndromes.

Authors:  C P Panayiotopoulos
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 4.  Valproate as a mainstay of therapy for pediatric epilepsy.

Authors:  Renzo Guerrini
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

5.  Valproate in children with newly diagnosed idiopathic generalized epilepsy.

Authors:  K D Holland; S Monahan; D Morita; G Vartzelis; T A Glauser
Journal:  Acta Neurol Scand       Date:  2010-01-06       Impact factor: 3.209

Review 6.  Molecular and therapeutic potential and toxicity of valproic acid.

Authors:  Sébastien Chateauvieux; Franck Morceau; Mario Dicato; Marc Diederich
Journal:  J Biomed Biotechnol       Date:  2010-07-29

Review 7.  Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research.

Authors:  Joost Willebrords; Isabel Veloso Alves Pereira; Michaël Maes; Sara Crespo Yanguas; Isabelle Colle; Bert Van Den Bossche; Tereza Cristina Da Silva; Cláudia Pinto Marques Souza de Oliveira; Wellington Andraus; Venâncio Avancini Alves; Bruno Cogliati; Mathieu Vinken
Journal:  Prog Lipid Res       Date:  2015-06-11       Impact factor: 16.195

8.  Current and emerging treatments for absence seizures in young patients.

Authors:  Pascal Vrielynck
Journal:  Neuropsychiatr Dis Treat       Date:  2013-07-15       Impact factor: 2.570

9.  Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents.

Authors:  Francesco Brigo; Stanley C Igwe; Simona Lattanzi
Journal:  Cochrane Database Syst Rev       Date:  2021-01-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.